Home

Articles from Fellow Health

Fellow Health Announces New York State Approval for Its Lab & Post-vasectomy Semen Analysis Kit
Fellow Health, a leading company focused on advancing male reproductive health through patient-centric testing solutions, today announced that it received a high-complexity laboratory permit from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) along with approval for its post-vasectomy semen analysis (PVSA). This milestone allows Fellow Health to offer its validated PVSA test in New York.
By Fellow Health · Via Business Wire · July 31, 2025
Fellow Health Closes a $24 Million Series B Financing to Expand its Male Reproductive Test Offerings
Fellow Health, a leading company focused on advancing male reproductive health through patient-centric testing solutions, announced today the close of a $24 million Series B financing round. The round was led by 5AM Ventures, with new participation from The Forest Road Company (Forest Road). The Series B adds to Fellow Health’s prior Series A and follow-on funding, bringing the company’s total capital raised to $48 million across all rounds.
By Fellow Health · Via Business Wire · July 15, 2025
Fellow Health to Present Innovative Research on Prostate Cancer Biomarkers and PVSA Testing at AUA 2025
Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the presentation of four posters at the American Urological Association (AUA) 2025 meeting, taking place April 26–29 in Las Vegas. The studies highlight mail-in semen analysis as a potential post-PSA reflex test as well as an alternative to in-clinic post-vasectomy semen analysis (PVSA).
By Fellow Health · Via Business Wire · April 28, 2025
Fellow Health Study Uncovers Source of Cell Free DNA in Seminal Fluid
Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, announced today the publication of a study titled “Tissue of origin characterization of cell free DNA in seminal plasma: Implications for new liquid biopsies” in PLOS One. The research shows that seminal plasma is a rich source of cell free DNA (cfDNA) from somatic cells and provides new insights into its potential as a liquid biopsy for several conditions.
By Fellow Health · Via Business Wire · April 2, 2025
Fellow Health Study Demonstrates 82% Compliance Rates with Mail-In Postvasectomy Semen Analysis
Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the findings of a study demonstrating the effectiveness of its mail-in postvasectomy semen analysis (PVSA) kits. The research, published in the Journal of Urology, found that Fellow Health’s mail-in testing significantly improves compliance rates, addressing longstanding challenges in verifying vasectomy success.
By Fellow Health · Via Business Wire · November 21, 2024
Fellow Health Celebrates Milestone of 100,000 Patient Tests
Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, recently achieved a significant milestone of delivering more than 100,000 patient test results since its product launch in 2020, highlighting its power to provide accurate and user-friendly testing for the male reproductive system.
By Fellow Health · Via Business Wire · October 31, 2024